August 30, 2007— Anesiva, Inc. (Nasdaq: ANSV) and Particle Therapeutics Limited have entered into an agreement granting Particle Therapeutics a specific-use license to incorporate Anesiva’s drug delivery technology into its needle-free, intradermal delivery system for glucagon, a hormone commonly used for the treatment of hypoglycemia associated with Type 1 and Type 2 diabetes... Anesiva's Press Release - Particle Therapeutics' Press Release -